title: Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.
abstract: The BRAF inhibitor vemurafenib can cause severe cutaneous reactions, including Stevens-Johnson syndrome, particularly when administered after ipilimumab, which usually prevents further drug administration. We report the case of a patient with Stevens-Johnson syndrome due to vemurafenib, who was retreated with vemurafenib with a program of slow desensitization with dexamethasone and diphenhydramine. Vemurafenib was tolerated at a 50% dose after a 3-week desensitization. Desensitization may be possible in patients who develop Stevens-Johnson syndrome after vemurafenib treatment.
authors: Center for Melanoma Research and Treatment, California Pacific Medical Center, San Francisco, California, USA. minord@sutterhealth.org
authors: David R
authors: DR
authors: Minor
authors: Robert
authors: R
authors: Rodvien
authors: Mohammed
authors: M
authors: Kashani-Sabet
mesh_terms: D003888:Desensitization, Immunologic / Q000379:methods*; D003907:Dexamethasone / Q000627:therapeutic use*; D004155:Diphenhydramine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000188:drug therapy* / Q000276:immunology; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D003907:Dexamethasone; D004155:Diphenhydramine